Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival

Eitemau Tebyg

• Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
  gan: Wester, Ruth, et al.
  Cyhoeddwyd: (2019)
• Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
  gan: Sonneveld, Pieter, et al.
  Cyhoeddwyd: (2015)
• Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
  gan: Wester, Ruth, et al.
  Cyhoeddwyd: (2020)
• Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology
  gan: Hazenberg, Bouke P.C., et al.
  Cyhoeddwyd: (2015)
• Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma
  gan: Broijl, Annemiek, et al.
  Cyhoeddwyd: (2016)